Sumitra Deb

4.6k total citations
79 papers, 3.5k citations indexed

About

Sumitra Deb is a scholar working on Oncology, Molecular Biology and Biotechnology. According to data from OpenAlex, Sumitra Deb has authored 79 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 41 papers in Molecular Biology and 16 papers in Biotechnology. Recurrent topics in Sumitra Deb's work include Cancer-related Molecular Pathways (46 papers), Cancer Research and Treatments (15 papers) and Epigenetics and DNA Methylation (14 papers). Sumitra Deb is often cited by papers focused on Cancer-related Molecular Pathways (46 papers), Cancer Research and Treatments (15 papers) and Epigenetics and DNA Methylation (14 papers). Sumitra Deb collaborates with scholars based in United States, United Kingdom and India. Sumitra Deb's co-authors include P Tegtmeyer, Mark A. Subler, Daniel W. Martin, Swati Palit Deb, A L DeLucia, Doris Brown, Andrew Koff, Catherine A. Vaughan, Raquel Muñoz and Katherine E. Stagliano and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Sumitra Deb

78 papers receiving 3.4k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Sumitra Deb 2.3k 2.2k 471 463 441 79 3.5k
Roger R. Beerli 2.6k 1.1× 4.0k 1.8× 228 0.5× 183 0.4× 775 1.8× 52 6.3k
Tapan K. Bera 1.0k 0.4× 1.5k 0.7× 258 0.5× 466 1.0× 340 0.8× 87 3.6k
Brad Ozanne 1.4k 0.6× 2.3k 1.0× 452 1.0× 123 0.3× 591 1.3× 63 3.9k
Pradip Raychaudhuri 2.0k 0.9× 4.5k 2.1× 749 1.6× 154 0.3× 1.1k 2.4× 92 5.6k
Berthold Henglein 1.7k 0.7× 2.1k 1.0× 321 0.7× 130 0.3× 443 1.0× 27 3.2k
Srilata Bagchi 1.4k 0.6× 2.1k 1.0× 301 0.6× 118 0.3× 981 2.2× 48 3.1k
Ali Fattaey 4.0k 1.7× 4.6k 2.1× 462 1.0× 622 1.3× 2.3k 5.2× 34 6.6k
Joe S. Mymryk 1.3k 0.6× 2.8k 1.3× 537 1.1× 148 0.3× 1.8k 4.2× 152 4.3k
Warren Maltzman 1.4k 0.6× 1.3k 0.6× 278 0.6× 440 1.0× 538 1.2× 15 2.1k
Harold E Varmus 776 0.3× 2.4k 1.1× 271 0.6× 94 0.2× 680 1.5× 25 3.7k

Countries citing papers authored by Sumitra Deb

Since Specialization
Citations

This map shows the geographic impact of Sumitra Deb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumitra Deb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumitra Deb more than expected).

Fields of papers citing papers by Sumitra Deb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumitra Deb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumitra Deb. The network helps show where Sumitra Deb may publish in the future.

Co-authorship network of co-authors of Sumitra Deb

This figure shows the co-authorship network connecting the top 25 collaborators of Sumitra Deb. A scholar is included among the top collaborators of Sumitra Deb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumitra Deb. Sumitra Deb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Das, Rajdeep, Sumitra Deb, & P.K. Suresh. (2025). TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses. Clinical and Experimental Medicine. 26(1). 25–25.
2.
Hu, Bin, et al.. (2023). Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment. International Journal of Molecular Sciences. 24(17). 13082–13082. 6 indexed citations
3.
Salles, Évila Lopes, Hesam Khodadadi, Vincenzo Costigliola, et al.. (2023). Inhalant cannabidiol impedes tumor growth through decreased tumor stemness and impaired angiogenic switch in NCI-H1437-induced human lung cancer model. Human Cell. 36(3). 1204–1210. 7 indexed citations
4.
Vaughan, Catherine A., Shilpa Singh, Steven R. Grossman, et al.. (2017). Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells. Molecular Oncology. 11(6). 696–711. 14 indexed citations
5.
Love, Ian M., Priyadarshan K. Damle, Nitai D. Mukhopadhyay, et al.. (2016). Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination. Molecular Cancer Research. 14(5). 423–436. 14 indexed citations
6.
Vaughan, Catherine A., Isabella Pearsall, W. Andrew Yeudall, Swati Palit Deb, & Sumitra Deb. (2014). p53: Its Mutations and Their Impact on Transcription. Sub-cellular biochemistry. 85. 71–90. 29 indexed citations
7.
Muhammad, Sajjad, Elizabeth Rosenberg, Jason M. Beckta, et al.. (2013). ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation. Clinical Cancer Research. 19(12). 3189–3200. 150 indexed citations
8.
Vaughan, Catherine A., Isabella Pearsall, Shilpa Singh, et al.. (2012). Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochemical and Biophysical Research Communications. 428(1). 6–10. 20 indexed citations
9.
10.
Vaughan, Catherine A., Brad Windle, & Sumitra Deb. (2012). ChIP Sequencing to Identify p53 Targets. Methods in molecular biology. 962. 227–236. 3 indexed citations
11.
Vaughan, Catherine A., Lathika Mohanraj, Sandeep K. Singh, et al.. (2011). Human Oncoprotein MDM2 Up-regulates Expression of NF- B2 Precursor p100 Conferring a Survival Advantage to Lung Cells. Genes & Cancer. 2(10). 943–955. 13 indexed citations
12.
Sankala, Heidi, Catherine A. Vaughan, Jing Wang, Sumitra Deb, & Paul R. Graves. (2011). Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Archives of Biochemistry and Biophysics. 512(1). 52–60. 30 indexed citations
13.
Ramamoorthy, Mahesh, et al.. (2009). MDM2 Controls the Timely Expression of Cyclin A to Regulate the Cell Cycle. Molecular Cancer Research. 7(8). 1253–1267. 21 indexed citations
14.
Scian, Mariano J., Katherine E. Stagliano, Michelle A. E. Anderson, et al.. (2005). Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression. Molecular and Cellular Biology. 25(22). 10097–10110. 131 indexed citations
15.
Scian, Mariano J., et al.. (2003). Transactivation and Transrepression Studies with p53. Humana Press eBooks. 234. 93–110. 2 indexed citations
16.
Ludes-Meyers, John, Mark A. Subler, Rubén M. Muñoz, et al.. (1996). Transcriptional Activation of the Human Epidermal Growth Factor Receptor Promoter by Human p53. Molecular and Cellular Biology. 16(11). 6009–6019. 152 indexed citations
17.
Brown, Doris, et al.. (1995). Wild-Type Human p53 Transactivates the Human Proliferating Cell Nuclear Antigen Promoter. Molecular and Cellular Biology. 15(12). 6785–6793. 103 indexed citations
18.
Martin, Daniel W., Raquel Muñoz, David J. Oliver, Mark A. Subler, & Sumitra Deb. (1994). Analysis of the DNA-Binding Domain of the HSV-1 Origin-Binding Protein. Virology. 198(1). 71–80. 23 indexed citations
19.
Deb, Sumitra, et al.. (1986). Domain Structure of the Simian Virus 40 Core Origin of Replication. Molecular and Cellular Biology. 6(5). 1663–1670. 146 indexed citations
20.
Viola, M. V., et al.. (1985). ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma.. The Journal of Experimental Medicine. 161(5). 1213–1218. 148 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roger R. Beerli Breakdown of academic impact, for papers by Tapan K. Bera Breakdown of academic impact, for papers by Brad Ozanne Breakdown of academic impact, for papers by Pradip Raychaudhuri Breakdown of academic impact, for papers by Berthold Henglein Breakdown of academic impact, for papers by Srilata Bagchi Breakdown of academic impact, for papers by Ali Fattaey Breakdown of academic impact, for papers by Joe S. Mymryk Breakdown of academic impact, for papers by Warren Maltzman Breakdown of academic impact, for papers by Harold E Varmus
Rankless by CCL
2026